PLX: יחס שווי שוק להכנסות החברה Protalix BioTherapeutics Inc.

The historical P/S chart allows for a valuation of Protalix BioTherapeutics relative to sales, where 2.90 indicates the value of this parameter. FDA patents and the costly compliance of ProCellEx laboratories create a defensive barrier for the company. Growth is driven by the success of the drug Elfabrio, licensing payments, and new clinical trials. An eco-friendly approach to protein synthesis in plants minimizes toxic waste and energy costs.

The P/S ratio compares market capitalization to annual revenue, reflecting the premium the market is willing to pay per unit of company income. This metric filters out speculative noise, which is critical for Protalix BioTherapeutics (PLX), as its commercial expansion depends on external partners; therefore, analyzing the company's normalized P/S helps avoid buying at peaks and protects capital from drawdowns.